Tykerb 250mg Tablet

About

Tykerb 250mg Tablet contains lapatinib, an oral, small-molecule tyrosine kinase inhibitor that targets both epidermal growth factor receptor (EGFR [ErbB1]) and human epidermal growth factor receptor 2 (HER2 [ErbB2]) pathways. By reversibly inhibiting the intracellular phosphorylation of these receptor tyrosine kinases, lapatinib blocks downstream signaling pathways involved in cell growth and proliferation, thereby inhibiting tumor cell growth. It is primarily used in the treatment of advanced or metastatic breast cancer that overexpresses HER2, often in combination with other chemotherapeutic agents like capecitabine or aromatase inhibitors. This targeted approach offers a crucial therapeutic option for patients who have progressed on prior therapies, aiming to improve progression-free survival and overall clinical outcomes.

Uses

• Treatment of advanced or metastatic HER2-positive breast cancer.
• Used in combination with capecitabine for specific indications.
• Used in combination with an aromatase inhibitor for specific indications.
• For patients who have progressed on prior therapies.

Directions For Use

Take orally, usually once daily, at least one hour before or one hour after a meal. Do not crush or chew.

Benefits

• Targets specific cancer growth pathways.
• Effective in HER2-positive breast cancer.
• Can be used in combination therapies.
• Oral administration for convenience.
• May improve progression-free survival.
• Offers an option for refractory cases.

Side Effects

• Diarrhea.
• Rash.
• Nausea.
• Vomiting.
• Fatigue.
• Stomatitis.
• Hand-foot syndrome.
• Anorexia.
• Dry skin.
• Dyspnea.
• Cardiac dysfunction (e.g., decreased LVEF).
• Hepatotoxicity.

Safety Measures

• Alcohol - Avoid or limit alcohol consumption, as it may exacerbate potential liver toxicity associated with lapatinib.
• Pregnancy - Contraindicated during pregnancy. Lapatinib can cause fetal harm. Effective contraception must be used during treatment and for at least 6 days after the last dose.
• Breastfeeding - Not recommended. It is unknown if lapatinib is excreted in human milk, but due to potential serious adverse reactions in breastfed infants, breastfeeding should be discontinued.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustment may be necessary, and liver function should be monitored regularly.
• Kidney - No specific dose adjustment is required for renal impairment, but caution is advised in severe cases.
• Lung - Use with caution in patients with pre-existing lung conditions. Interstitial lung disease/pneumonitis has been reported, though rarely.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.